The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: There is preliminary evidence suggesting saffron may effectively treat menopausal symptoms. The aim of this study was to examine the tolerability and efficacy of a standardised saffron extract (affron®) on menopausal complaints in perimenopausal women. Methods: In this 12-week, parallel-group, double-blind, randomised controlled trial, 86 perimenopausal women experiencing menopausal complaints received either a placebo or 14 mg of a saffron extract (affron®), twice daily. Outcome measures included the Greene Climacteric Scale (GCS), Positive and Negative Affect Schedule (PANAS), and Short Form-36 Health Survey (SF-36). Results: Based on data collected from 82 participants, saffron was associated with greater improvements in mood and psychological symptoms compared to the placebo. Results from the GCS revealed a significantly greater reduction in the GCS psychological score (P = 0.032), characterised by a 33% reduction in anxiety and a 32% reduction in depression scores from baseline to week 12. There was also a significantly greater reduction in the PANAS negative affect score (P = 0.043) compared to the placebo. However, compared to the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life measures. Saffron intake was well tolerated with no reported major adverse events. Conclusions: The saffron extract, affron®, administered for 12 weeks at a dose of 14 mg twice daily was associated with greater improvements in psychological symptoms. Further studies in perimenopausal women presenting with varying severity of menopausal symptoms, using different doses of saffron will be useful to examine in future clinical trials.
Abstract
Objectives: There is preliminary evidence suggesting saffron may effectively treat menopausal symptoms. The aim of this study was to examine the tolerability and efficacy of a standardised saffron extract (affron®) on menopausal complaints in perimenopausal women. Methods: In this 12-week, parallel-group, double-blind, randomised controlled trial, 86 perimenopausal women experiencing menopausal complaints received either a placebo or 14 mg of a saffron extract (affron®), twice daily. Outcome measures included the Greene Climacteric Scale (GCS), Positive and Negative Affect Schedule (PANAS), and Short Form-36 Health Survey (SF-36). Results: Based on data collected from 82 participants, saffron was associated with greater improvements in mood and psychological symptoms compared to the placebo. Results from the GCS revealed a significantly greater reduction in the GCS psychological score (P = 0.032), characterised by a 33% reduction in anxiety and a 32% reduction in depression scores from baseline to week 12. There was also a significantly greater reduction in the PANAS negative affect score (P = 0.043) compared to the placebo. However, compared to the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life measures. Saffron intake was well tolerated with no reported major adverse events. Conclusions: The saffron extract, affron®, administered for 12 weeks at a dose of 14 mg twice daily was associated with greater improvements in psychological symptoms. Further studies in perimenopausal women presenting with varying severity of menopausal symptoms, using different doses of saffron will be useful to examine in future clinical trials.
참고문헌 (35)
- Harlow SD, "Executive summary of the Stages of Reproductive Aging Workshop + 10 addressing the unfinished agenda of staging reproductive aging", Menopause, 19, pp.387~395 (2012)
- Davis SR, "Menopause", Nat Rev Dis Primers, 1, pp.15004~ (2015)
- Santoro N, "Menopausal symptoms and their management", Endocrinol Metab Clin North Am, 44, pp.497~515 (2015)
- Ji MX, "Primary osteoporosis in postmenopausal women", Chronic Dis Transl Med, 1, pp.9~13 (2015)
- Kozakowski J, "Obesity in menopause-our negligence or an unfortunate inevitability", Prz Menopauzalny, 16, pp.61~65 (2017)
- Rosano GM, "Menopause and cardiovascular disease : the evidence", Climacteric, 10(Suppl 1), pp.19~24 (2007)
- Martin KA, "Approach to the patient with menopausal symptoms", J Clin Endocrinol Metab, 93, pp.4567~4575 (2008)
- Eisenberger A, "Hormone replacement therapy and venous thromboembolism", J Steroid Biochem Mol Biol, 142, pp.76~82 (2014)
- Henderson VW, "Hormone therapy and the risk of stroke : perspectives 10 years after the Women's Health Initiative trials", Climacteric, 15, pp.229~234 (2012)
- Fait T, "Menopause hormone therapy : latest developments and clinical practice", Drugs Context, 8, pp.212551~ (2019)
- Wu CK, "Antidepressants during and after menopausal transition: a systematic review and meta-analysis", Sci Rep, 10, pp.8026~ (2020)
- Javadi B, "A survey on saffron in major islamic traditional medicine books", Iran J Basic Med Sci, 16, pp.1~11 (2013)
- Hosseinzadeh H, "Avicenna's(Ibn Sina)the Canon of Medicine and saffron(Crocus sativus) : a review", Phytother Res, 27, pp.475~483 (2013)
- Marx W, "Effect of saffron supplementation on symptoms of depression and anxiety : a systematic review and meta-analysis", Nutr Rev, 77, pp.557~571 (2019)
- Kashani L, "Efficacy of Crocus sativus(saffron)in treatment of major depressive disorder associated with post-menopausal hot flashes : a double-blind, randomized, placebo-controlled trial", Arch Gynecol Obstet, 297, pp.717~724 (2018)
- Taavoni S, "Effect of Tribulus terrestris, ginger, saffron, and Cinnamomum on menopausal symptoms : a randomised, placebo-controlled clinical trial", Prz Menopauzalny, 16, pp.19~22 (2017)
- Mahdavian M, "Effect of the mixed herbal medicines extract(fennel, chamomile, and saffron)on menopause syndrome : a randomized controlled clinical trial", J Caring Sci, 8, pp.181~189 (2019)
- Greene JG, "Constructing a standard climacteric scale", Maturitas, 29, pp.25~31 (1998)
- Moradi F, "The effect of hormone replacement therapy on cognitive function in postmenopausal women : an RCT", Int J Reprod Biomed, 16, pp.767~774 (2018)
- Watson D, "Development and validation of brief measures of positive and negative affect : the PANAS scales", J Pers Soc Psychol, 54, pp.1063~1070 (1988)
- Díaz-García A, "Positive and Negative Affect Schedule(PANAS) : psychometric properties of the online Spanish version in a clinical sample with emotional disorders", BMC Psychiatry, 20, pp.56~ (2020)
- Ware JE Jr, "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection", Med Care, 30, pp.473~483 (1992)
- McHorney CA, "The MOS 36-Item ShortForm Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs", Med Care, 31, pp.247~263 (1993)
- Hays RD, "The RAND 36-Item Health Survey 1.0", Health Econ, 2, pp.217~227 (1993)
- Tabachnick BG, "Using multivariate statistics" (2007), Pearson Allyn and Bacon
- Lopresti AL, "Saffron(Crocus sativus)for depression : a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action", Hum Psychopharmacol, 29, pp.517~527 (2014)
- Anderson G, "Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression : therapeutic implications", CNS Drugs, 28, pp.1~10 (2014)
- Davis J, "Towards a classification of biomarkers of neuropsychiatric disease : from encompass to compass", Mol Psychiatry, 20, pp.152~153 (2015)
- Ahmad B, "Protective effects of saffron against zearalenone-induced alterations in reproductive hormones in female mice(Mus musculus)", Clin Exp Reprod Med, 45, pp.163~169 (2018)
- Zohrabi D, "Effects of crocin on the Pituitary-Gonadal axis and hypothalamic Kiss-1gene expression in female Wistar rats", Int J Fertil Steril, 12, pp.56~60 (2018)
- Vasegh M, "Investigating effects of hydroalcoholic extract of saffron on sex hormones in female rats undergoing chemotherapy with cyclophosphamide", Comp Clin Pathol, 24, pp.399~402 (2015)
- Ai J, "Effect of aqueous extract of Crocus sativus L. (saffron) stigma on serum levels of gonadotropins and folliculogenesis in adult rats", J Appl Anim Res, 35, pp.49~52 (2009)
- Koebele SV, "Modeling menopause : the utility of rodents in translational behavioral endocrinology research", Maturitas, 87, pp.5~17 (2016)
- Lopresti AL, "Efficacy of a standardised saffron extract(affron®)as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults : a randomised, double-blind, placebo-controlled study", J Psychopharmacol, 33, pp.1415~1427 (2019)
- Khilare V, "Multiple tests on saffron find new adulterant materials and reveal that Ist grade saffron is rare in the market", Food Chem, 272, pp.635~642 (2019)